2 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
New Investigator Awards in Alzheimer's Disease
Funded by The Rosalinde and Arthur Gilbert Foundation and The Diane and Guilford Glazer Foundation, the major goal of this partnership program is to support important research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, and treatment of Alzheimer's disease. The program also serves to encourage junior investigators in the United States and Israel to pursue research and academic careers in the neurosciences, and Alzheimer's disease in particular.
Projects in basic and translational research related to Alzheimer's disease (AD) that are clinically relevant, will be considered. Projects that focus on healthy brain aging are also considered. For one of the awards, priority may be given to an investigator with a research interest related to healthy brain aging. Areas of research could for example include learning and memory, nutrition, exercise, cardiovascular risk factors, as they relate to the brain and the aging process.
Examples of promising areas of research include, but are not limited to:
Basic mechanisms of aging in the central nervous system
Learning and memory
The Biology and Pathobiology of Synapses
Genetics of AD
Neuroimaging and precursors of AD
Cellular and Molecular pathways of AD
Biological Markers of AD
Exercise, nutrition and dietary factors
Neurogenesis and AD
Impact of environmental agents in CNS aging and early AD
Cardiovascular and cerebrovascular factors
It is anticipated that up to 4 grants of $100,000 each will be awarded in 2014. Applicants may propose to use the award over the course of one or two years as justified by the proposed research. Up to 8% of funds may be budgeted for overhead or indirect costs (not to exceed $7,407). Funding will begin July 1, 2014.
The applicant must be an independent investigator with independent research space as described in a form completed by the Dean or Department Chair, and must be no more than 10 years beyond start of postdoctoral research training as of July 1, 2014. Exceptions to the ten year rule may be requested for unusual circumstances by emailing an NIH-style biosketch to AFAR at email@example.com. The proposed research must be conducted at any type of not-for-profit setting in the United States or Israel.
The New Investigator Awards in Alzheimer's Disease do not provide support for:
Postdoctoral fellows in the laboratory of a senior investigator
Investigators who have already received major extramural funding (such as an R01 or NSF equivalent grant)
Senior faculty, i.e. at the rank of Associate Professor level or higher
NIH Intramural program employees
Applicants who are conducting research at a for-profit institution, or at an institution outside of the United States or Israel
Applicants cannot apply for the 2014 AFAR Research Grant Program or Glenn/AFAR BIG Program. Applications for this program will be considered for the AFAR Research Grant if deemed competitive.
Five criteria are used to determine the merit of an application:
Qualifications of the applicant;
Quality of the proposed research;
Relevance of the proposal to how mechanisms of aging may lead to AD or encourage healthy brain aging;
Excellence of the research environment;
Likelihood that the project will advance the applicant's career in basic research on the mechanisms of aging and AD or healthy brain aging
For one of the awards, priority may be given to an investigator with a research interest related to healthy brain aging provided the application is deemed to meet the highest standards set by AFAR's Research Committee.
The deadline for receipt of all Letters of Intent is December 16, 2013 at 5:00 p.m. EST. Please refer to the New Investigator LOI instructions. Incomplete LOIs cannot be considered. All applications and supporting materials must be submitted through the website www.afar.org/grants/. The Letters of Intent will be reviewed by a committee. Applicants will be notified by January 31, 2014, and a subset of applicants will be invited to submit a full application by March 17, 2014.
All LOI candidates who are invited to submit applications must have it endorsed by their institution. Final awards are announced by early June. The award start date is July 1, 2014. AFAR will not provide reviewer critiques to any applicants at any review level.
Investigators will be required to submit a brief narrative report on the progress of their research five months after the start date of the award. Final narrative and financial reports are required within three months following the end date of the award.
The award recipients are expected to attend the AFAR Grantee Conference which convenes AFAR grant recipients, mentors and leaders in the field to review and disseminate the research progress of the grantees and their findings. The meeting encourages networking, facilitates collaborations, and enhances the development of leadership. In addition, grant recipients of the New Investigator Awards in Alzheimer's are expected to attend a special session at the grantee conference.
Request for Applications: Leukemia & Lymphoma Society Screen to Lead Program
The Leukemia & Lymphoma Society (LLS) is sponsoring and issuing this Request for Applications (RFA) from qualified academic laboratories for drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators to receive resources for high-throughput screening and optimization of small molecules into drug-like compounds suitable for in vivo testing in a disease-relevant model that can be used for further preclinical proof-of-concept testing of the new drug target. Last year, the first year of this new funding mechanism, 6 projects were chosen for funding by an acclaimed peer review panel. This year, new laboratories/projects will be selected to participate in this model of collaboration whereby LLS, grantee, sponsoring institution and appropriate contract service organizations (CROs) or core facilities at academic institutions work together to develop compounds with the potential to change the standard of care for patients with blood cancer. Continued funding/sponsorship will be contingent on available funds and assessments of progress toward the goals outlined in each individual proposal accepted by LLS.
The goal of this RFA is the development of small molecule for in vivo proof of concept studies in disease relevant animal models for hematological malignancies. Proposals should include strong scientific rationale for a new drug target in a hematological malignancy; provide information to assess existing intellectual property or the potential for novel chemical space; demonstrate or explain how a screening assay can be developed to accommodate a high volume of compounds; or indicate how a tractable lead compound can be further developed.
Investigators at academic laboratories are eligible to apply. Investigators must demonstrate that their research environment is equipped and suitable for aspects of the work plan that would be carried out at their facility or in their lab rather than at a CRO. Collaborations between multiple investigators to strengthen the work proposed will be considered favorably, but are not a requirement. Applicants need not be United States (U.S.) citizens nor associated with a U.S.-based institution. Applicants should hold a Ph.D., M.D., D.V.M. or equivalent degree.
APPLICATION and AWARD INFORMATION
LLS plans to sponsor several awards during this year of this program. It is anticipated that each project will be unique and the cost of each work plan variable, depending on the nature of the work required. For this reason, applicants will need to submit a proposed work plan (subject to modification by LLS and collaborators upon review) and a proposed budget with justification for its relationship to the work plan. These factors will be evaluated as part of the peer review application process. As collaborators in CROs or core facilities may conduct the greater portion of the work, LLS will coordinate the appropriate contracting for services according to the work plan. LLS will work with applicants to determine where the work should be conducted and help to manage the process. For any budgeted line items that are specifically related to the PI, for work conducted in their laboratory, indirect costs will be capped at 11.1%. Any new intellectual property created through this collaboration shall be owned and managed by the academic institution. LLS and CRO subcontractors shall assign all ownership rights to the institution. LLS will put in place, as it does with all its grants, an IP policy that must be executed by the researcher and researcher's academic institution at the time the application is submitted.
Applicants should include the following in their application:
Scientific rationale for novel target in hematologic malignancies and summary of supportive data;
Characterization of existing compounds, where appropriate;
A summary of the intellectual property landscape (to the best of knowledge) on the target/chemical space;
Description of unmet medical need, i.e., what therapeutic deficiency will this new drug target address; and
Capabilities of support from laboratory (i.e., describing the level of throughput for assays applicants propose to run in their laboratories)
APPLICATION FORMAT and SUBMISSION
Application templates are web-based and may be obtained on our website at: http://lls.fluxx.io under Screen to Lead Program. Applications are restricted to the capacity of the web forms. The form for budgets allows multi-year entries but only the first year is considered for this award. Please include only costs associated with your institution. Any CRO costs, if needed, will be determined by LLS and added to your budget. If you have had prior discussions with a CRO and have a budget estimate, you are welcome to upload this under the appropriate section but no other supporting documentation is allowed except the signed IP policy which is part of the RFA and must be included with your application.
The cut off for the receipt of applications is on the following date/time schedule:
Deadline: December 15, 2013, 3:00 p.m., ET
Scientific Peer Review Committee: April 2014
Notification of Awards: May 30, 2014
Anticipated Funding Start Date: October 2014
DESCRIPTION of PEER REVIEW PROCESS
Each application will undergo a thorough review that consists of two parts. There will be an internal review by LLS Research staff for compliance with guidelines, eligibility, and responsiveness of the project to the RFA. The internal review may involve additional requests for more detailed information on the project and direct discussions between the PI and LLS Research staff regarding the proposal to assess the appropriateness of the project.
There will be a second review hosted by LLS that is a more extensive external peer review by experts in drug discovery and development, medicinal chemistry, and hematological malignancies.
The application will be assessed upon the following criteria:
Scientific Rationale and Supportive Data
Unmet Medical Need/Scientific Impact
Research Plan & Feasibility
Resources & Qualifications of the PI